Search
Agmatine
go.drugbank.com/drugs/DB08838ExperimentalAgmantine is a natural metabolite of the amino acid arginine. It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges...
Categories: NMDA Receptor AntagonistsLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalHycanthone was approved by the FDA in 1975 but is no longer used.
Transmembrane anterior posterior transformation protein 1 homolog
go.drugbank.com/bio_entities/BE0003506TargetHumansPlays a role in primary cilia formation (PubMed:26365339). May act as a downstream effector of HOXC8 possibly by transducing or transmitting extracellular information required for axial skeletal patterning during development (By similari...
Synonyms: Cytomegalovirus partial fusion receptorFunction: growth hormone-releasing hormone receptor activityIdarucizumab
go.drugbank.com/drugs/DB09264ApprovedApproved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.
Benzonatate
go.drugbank.com/drugs/DB00868ApprovedBenzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.
Categories: Decreased Tracheobronchial Stretch Receptor ActivityDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigational[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.
Products: Nra-dapagliflozinLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]